• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌和靶向治疗-卡培他滨-氟维司群：ASCO 快速推荐更新。

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

机构信息

Dana Farber Cancer Institute, Boston, MA.

University of Pennsylvania, Philadelphia, PA.

出版信息

J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.

DOI:10.1200/JCO.24.00248
PMID:38478799
Abstract

.

摘要

.

相似文献

1
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌和靶向治疗-卡培他滨-氟维司群：ASCO 快速推荐更新。
J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.
2
Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.检测突变以指导激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的治疗：ASCO 指南快速推荐更新。
J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.
3
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.早期乳腺癌的最佳辅助化疗和靶向治疗——细胞周期蛋白依赖性激酶 4 和 6 抑制剂：ASCO 指南快速推荐更新。
J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.
4
Systemic Therapy Update on Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.镥-PSMA-617用于转移性去势抵抗性前列腺癌的系统治疗更新：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2024 Nov;42(31):3751-3752. doi: 10.1200/JCO.23.02128. Epub 2023 Nov 6.
5
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.人表皮生长因子受体2阴性转移性乳腺癌的化疗和靶向治疗：内分泌预处理或激素受体阴性患者的美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2022 Sep 10;40(26):3088-3090. doi: 10.1200/JCO.22.01533. Epub 2022 Aug 4.
6
Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.Ⅲ期非小细胞肺癌的治疗管理：ASCO 指南快速推荐更新。
J Clin Oncol. 2024 Sep 1;42(25):3058-3060. doi: 10.1200/JCO-24-01324. Epub 2024 Jul 23.
7
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.内分泌治疗后或激素受体阴性转移性乳腺癌的化疗与靶向治疗：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Feb 20;41(6):1318-1320. doi: 10.1200/JCO.22.02807. Epub 2023 Jan 10.
8
Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.转移性肾透明细胞癌的管理：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Nov 20;41(33):5184-5186. doi: 10.1200/JCO.23.01977. Epub 2023 Oct 9.
9
Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.癌症恶病质：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Sep 1;41(25):4178-4179. doi: 10.1200/JCO.23.01280. Epub 2023 Jul 12.
10
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.Ⅲ期非小细胞肺癌的管理：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Sep 20;41(27):4430-4432. doi: 10.1200/JCO.23.01261. Epub 2023 Jul 20.

引用本文的文献

1
Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer.卡哌西他滨/氟维司群用于激素受体阳性、人表皮生长因子受体2低表达或人表皮生长因子受体2阴性的局部晚期或转移性乳腺癌患者。
Ther Adv Med Oncol. 2025 Jul 31;17:17588359251358947. doi: 10.1177/17588359251358947. eCollection 2025.
2
Capivasertib-induced polymorphous lichenoid exanthem: Report of a novel AKT kinase inhibitor-related drug eruption.卡匹西利诱导的多形性苔藓样疹：一种新型AKT激酶抑制剂相关药疹的报告。
JAAD Case Rep. 2025 Jun 14;62:96-99. doi: 10.1016/j.jdcr.2025.05.022. eCollection 2025 Aug.
3
A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer.
一项关于哌柏西利联合内分泌治疗加或不加短期化疗用于HR阳性HER2阴性转移性乳腺癌一线治疗的真实世界研究。
Front Oncol. 2025 Jul 9;15:1512496. doi: 10.3389/fonc.2025.1512496. eCollection 2025.
4
Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterations.基于乳腺癌组织和血液的二代测序结果在检测PIK3CA、AKT1和PTEN改变方面的回顾性比较。
Breast Cancer Res. 2025 Jul 1;27(1):122. doi: 10.1186/s13058-025-02055-0.
5
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.用于治疗雌激素受体阳性晚期乳腺癌的蛋白酶靶向嵌合体（PROTAC）雌激素受体降解剂
Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6.
6
Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition).PI3K/AKT/mTOR抑制剂治疗乳腺癌临床应用专家共识（2025年版）
Cancer Innov. 2025 Apr 9;4(3):e70008. doi: 10.1002/cai2.70008. eCollection 2025 Jun.
7
Identification of thyroid cancer biomarkers using WGCNA and machine learning.使用加权基因共表达网络分析（WGCNA）和机器学习鉴定甲状腺癌生物标志物
Eur J Med Res. 2025 Apr 5;30(1):244. doi: 10.1186/s40001-025-02466-x.
8
An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.一项支持新型AKT抑制剂卡匹西利剂量的暴露安全性分析。
Cancer Chemother Pharmacol. 2025 Mar 28;95(1):48. doi: 10.1007/s00280-025-04775-8.
9
Capecitabine with aromatase inhibitors in the front-line therapy for metastatic breast cancer.卡培他滨联合芳香化酶抑制剂用于转移性乳腺癌的一线治疗。
Breast Cancer. 2025 Mar 27. doi: 10.1007/s12282-025-01695-6.
10
Organoid models: applications and research advances in colorectal cancer.类器官模型：在结直肠癌中的应用与研究进展
Front Oncol. 2025 Feb 7;15:1432506. doi: 10.3389/fonc.2025.1432506. eCollection 2025.